Portion

<!-- Name:DistributionId Value:8788605 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized…

NEW YORK, Nov. 16, 2022 /PRNewswire/ -- INX Limited today announced the calculation of its cumulative Adjusted Operating Cash Flow as of September 30, 2022 and the pro rata portion of the Distributable Amount per INX Token. (U.S. Dollars…